MBRX Moleculin Biotech Inc: רווח למניה אחת ב-12 החודשים האחרונים

Moleculin Biotech, Inc. (MBRX) develops small molecules to combat aggressive cancer, leveraging high scientific credibility. R&D activities are accompanied by strict compliance with environmental regulations regarding chemical disposal. The current EPS YoY TTM trajectory, where the parameter equals 85.20, demonstrates the capitalization's resilience to Fed rates, which is critical for the success of anthracycline trials and patient survival rates.
Moleculin Biotech, Inc. - פילוחים אנליטיים ומדדי מפתח (MBRX)

This indicator captures the dynamics of net income per share over a trailing twelve-month period, allowing for an assessment of the business's actual capitalization rate relative to previous periods. By analyzing the annual EPS TTM YoY trend, an investor can distinguish random market spikes from systemic growth, which is critically important for Moleculin Biotech, Inc. (MBRX) given its high capital burn rate and the toxicity risks associated with its oncology drug pipeline.